VTX3232

VTX3232 is an oral, CNS-penetrant, potent and selective small molecule inhibitor of the NLRP3 inflammasome developed by Ventyx Biosciences. The drug is designed to block the activity of the NLRP3 protein complex in the central nervous system (CNS), thereby reducing neuroinflammation. Activation of the NLRP3 inflammasome leads to release of pro-inflammatory cytokines such as interleukin-1β (IL-1β) and IL-18; excessive activation is implicated in neurodegenerative diseases like Parkinson’s disease. In clinical studies, VTX3232 demonstrated strong target engagement with significant reductions in biomarkers associated with NLRP3 activation (including IL-1β and IL-18) in both plasma and cerebrospinal fluid. The drug has shown safety and tolerability in early-stage Parkinson’s patients, along with improvements in motor and non-motor symptoms. It is also being investigated for obesity, cardiometabolic risk factors, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and other neuroinflammatory conditions[1][4][5][6][7][8][9].

Other names

NLRP3 inflammasome inhibitorNLRP-3 inflammasome inhibitorNLRP 3 inflammasome inhibitor